Morbidity, mortality, and management of methicillin-resistant S. aureus bacteremia in the USA: update on antibacterial choices and understanding

References

• Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37:1288–1301. Epub 2016/10/22.
   PubMed Web of Science ®Google Scholar
• Wolfe CM, Cohen B, Larson E. Prevalence and risk factors for antibiotic-resistant community-associated bloodstream infections. J Infect Public Health. 2014;7:224–232.
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr., Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003;163:2066–2072.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Active bacterial core surveillance report, emerging infections program network, methicillin-resistant Staphylococcus aureus, 2015. Available via the Internet: https://www.cdc.gov/hai/eip/pdf/2015-mrsa-annual-summary.pdf. Accessed 2018 Jan 18.
   Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–e55.
   PubMed Web of Science ®Google Scholar
• Moise PA, Amodio-Groton M, Rashid M, et al. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant beta-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother. 2013;57:1192–1200, Epub 2012/12/21.
   PubMed Web of Science ®Google Scholar
• Kullar R, Davis SL, Levine DP, et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52:975–981, Epub 2011/04/05.
   PubMed Web of Science ®Google Scholar
• Kullar R, Casapao AM, Davis SL, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013;68:2921–2926.
   PubMed Web of Science ®Google Scholar
• Sharma M, Riederer K, Chase P, et al. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2008;27:433–437.
   PubMed Web of Science ®Google Scholar
• Paul M, Kariv G, Goldberg E, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010;65:2658–2665.
   PubMed Web of Science ®Google Scholar
• Rhee Y, Aroutcheva A, Hota B, et al. Evolving epidemiology of Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol. 2015;36:1417–1422.
   PubMed Web of Science ®Google Scholar
• David MZ, Daum RS, Bayer AS, et al. Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008–2011: significant geographic variation in community-onset infections. Clin Infect Dis. 2014;59:798–807.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National and state healthcare-associated infections progress report. Published March, 2016. Available at www.cdc.gov/hai/progress-report/index.html. 2014.
   Google Scholar
• Centers for Disease Control and Prevention. Healthcare-associated infections in the United States, 2006–2016: a story of progress. Available at: https://www.cdc.gov/hai/surveillance/data-reports/data-summary-assessing-progress.html. Accessed 2018 Jan 19.
   Google Scholar
• Han JH, Edelstein PH, Bilker WB, et al. The effect of staphylococcal cassette chromosome mec (SCCmec) type on clinical outcomes in methicillin-resistant Staphylococcus aureus bacteremia. J Infect. 2013;66:41–47.
   PubMed Web of Science ®Google Scholar
• Han JH, Edelstein PH, Lautenbach E. Reduced vancomycin susceptibility and staphylococcal cassette chromosome mec (SCCmec) type distribution in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2012;67:2346–2349.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Jensen SO, Vaska VL, et al. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012;25:362–386.
   PubMed Web of Science ®Google Scholar
• Tong SY, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28:603–661.
   PubMed Web of Science ®Google Scholar
• Chong YP, Park SJ, Kim HS, et al. Persistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates. Medicine (Baltimore). 2013;92:98–108.
   PubMed Web of Science ®Google Scholar
• Rieg S, Peyerl-Hoffmann G, de With K, et al. Mortality of S. aureus bacteremia and infectious diseases specialist consultation – a study of 521 patients in Germany. J Infect. 2009;59:232–239.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54:755–771.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Van Schooneveld TC, Fey PD, et al. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA. 2014;312:1552–1564.
   PubMed Web of Science ®Google Scholar
• Baxi SM, Clemenzi-Allen A, Gahbauer A, et al. Vancomycin MIC does not predict 90-day mortality, readmission, or recurrence in a prospective cohort of adults with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2016;60:5276–5284.
   PubMed Web of Science ®Google Scholar
• Joo EJ, Park DA, Kang CI, et al. Reevaluation of the impact of methicillin-resistance on outcomes in patients with Staphylococcus aureus bacteremia and endocarditis. Korean J Intern Med. 2018. DOI: 10.3904/kjim.2017.098.
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53–59.
   PubMed Web of Science ®Google Scholar
• Yaw LK, Robinson JO, Ho KM. A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study. Lancet Infect Dis. 2014;14:967–975.
   PubMed Web of Science ®Google Scholar
• Goto M, Schweizer ML, Vaughan-Sarrazin MS, et al. Association of evidence-based care processes with mortality in Staphylococcus aureus bacteremia at Veterans Health Administration hospitals, 2003–2014. JAMA Intern Med. 2017;177:1489–1497.
   PubMed Web of Science ®Google Scholar
• Timbrook TT, Morton JB, McConeghy KW, et al. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis. 2017;64:15–23.
   PubMed Web of Science ®Google Scholar
• Buehrle K, Pisano J, Han Z, et al. Guideline compliance and clinical outcomes among patients with Staphylococcus aureus bacteremia with infectious diseases consultation in addition to antimicrobial stewardship-directed review. Am J Infect Control. 2017;45:713–716.
   PubMed Web of Science ®Google Scholar
• Filice GA, Nyman JA, Lexau C, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010;31:365–373.
   PubMed Web of Science ®Google Scholar
• Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol. 2009;30:453–460.
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Mavros MN, Roussos N, et al. Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. Mayo Clin Proc. 2012;87:349–363.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57:734–744.
   PubMed Web of Science ®Google Scholar
• Carreno JJ, Kenney RM, Lomaestro B. Vancomycin-associated renal dysfunction: where are we now? Pharmacotherapy. 2014;34:1259–1268.
   PubMed Web of Science ®Google Scholar
• Hanrahan T, Whitehouse T, Lipman J, et al. Vancomycin-associated nephrotoxicity: a meta-analysis of administration by continuous versus intermittent infusion. Int J Antimicrob Agents. 2015;46:249–253.
   PubMed Web of Science ®Google Scholar
• Hao JJ, Chen H, Zhou JX. Continuous versus intermittent infusion of vancomycin in adult patients: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;47:28–35.
   PubMed Web of Science ®Google Scholar
• Kullar R, Leonard SN, Davis SL, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15–20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy. 2011;31:441–448.
   PubMed Web of Science ®Google Scholar
• Prybylski JP. Vancomycin trough concentration as a predictor of clinical outcomes in patients with Staphylococcus aureus bacteremia: a meta-analysis of observational studies. Pharmacotherapy. 2015;35:889–898.
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Golan Y, Lamp KC, et al. Daptomycin in the treatment of bacteremia. Am J Med. 2007;120:S21–S7.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ruiz A, Gargalianos-Kakolyris P, Timerman A, et al. Daptomycin in the clinical setting: 8-year experience with gram-positive bacterial infections from the EU-CORE(SM) registry. Adv Ther. 2015;32:496–509.
   PubMed Web of Science ®Google Scholar
• Moise PA, Culshaw DL, Wong-Beringer A, et al. Comparative effectiveness of vancomycin versus daptomycin for MRSA bacteremia with vancomycin MIC >1 mg/L: a multicenter evaluation. Clin Ther. 2016;38:16–30.
   PubMed Web of Science ®Google Scholar
• Claeys KC, Zasowski EJ, Casapao AM, et al. Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2016;60:5841–5848.
   PubMed Web of Science ®Google Scholar
• Seaton RA, Gonzalez-Ruiz A, Cleveland KO, et al. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob. 2016;15:18.
   PubMed Web of Science ®Google Scholar
• Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149–2152.
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, et al. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a worldwide surveillance programme (2005–2012). Int J Antimicrob Agents. 2014;43:465–469.
   PubMed Web of Science ®Google Scholar
• Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev. 2013;26:759–780.
   PubMed Web of Science ®Google Scholar
• Casapao AM, Leonard SN, Davis SL, et al. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bloodstream infection. Antimicrob Agents Chemother. 2013;57:4252–4259.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services/Centers for Disease Control and Prevention. Final 2015 reports of nationally notifiable infectious diseases and conditions. MMWR. 2016;65:1306–1321.
   PubMed Web of Science ®Google Scholar
• Zhang S, Sun X, Chang W, et al. Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. PLoS One. 2015;10:e0136082.
   PubMed Web of Science ®Google Scholar
• Vancomycin hydrochloride for injection, USP [package insert]. Lake Forest, IL: Hospira, Inc; 2017. Available at http://labeling.pfizer.com/ShowLabeling.aspx?id=4645.
   Google Scholar
• CUBICIN® [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2017. Available at https://www.merck.com/product/usa/pi_circulars/c/cubicin/cubicin_pi.pdf.
   Google Scholar
• TEFLARO® (ceftaroline fosamil), USP [package insert]. New York, NY: Forest Pharmaceuticals, Inc; 2016. Available at https://www.allergan.com/assets/pdf/teflaro_pi.
   Google Scholar
• Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49:1127–1134.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Cegelski L, Stueber D, et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol. 2008;377:281–293.
   PubMed Web of Science ®Google Scholar
• Belley A, Neesham-Grenon E, McKay G, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother. 2009;53:918–925.
   PubMed Web of Science ®Google Scholar
• Belley A, McKay GA, Arhin FF, et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother. 2010;54:5369–5371.
   PubMed Web of Science ®Google Scholar
• DALVANCE® (dalbavancin) for injection [package insert]. Parsippany, NJ: Durata Therapeutics US Limited; 2016. Available at https://www.allergan.com/assets/pdf/dalvance_pi.
   Google Scholar
• ORBACTIV® (oritavancin), [package insert]. Parsippany, NJ: The Medicines Company; 2016. Available at http://www.orbactiv.com/pdfs/orbactiv-prescribing-information.pdf.
   Google Scholar
• VIBATIV® (telavancin), USP [package insert]. South San Francisco, CA: Theravance Biopharma US, Inc; 2016. Available at: https://www.vibativ.com/pdf/PrescribingInformation.pdf.
   Google Scholar
• Sader HS, Mendes RE, Streit JM, et al. Antimicrobial susceptibility trends among Staphylococcus aureus isolates from U.S. hospitals: results from 7 years of the ceftaroline (AWARE) surveillance program, 2010–2016. Antimicrob Agents Chemother. 2017;61:e01043-17.
   PubMed Web of Science ®Google Scholar
• Duncan LR, Sader HS, Flamm RK, et al. Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013–2014). Diagn Microbiol Infect Dis. 2016;86:303–306.
   PubMed Web of Science ®Google Scholar
• Sader HS, Mendes RE, Duncan LR, et al. Antimicrobial activity of dalbavancin tested against Staphylococcus aureus with decreased susceptibility to glycopeptides, daptomycin, and/or linezolid from United States medical centers. Antimicrob Agents Chemother. 2017. DOI: 10.1128/AAC.02397-17
   Web of Science ®Google Scholar
• Mendes RE, Sader HS, Smart JI, et al. Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011–2014). Eur J Clin Microbiol Infect Dis. 2017;36:1013–1017.
   PubMed Web of Science ®Google Scholar
• McCurdy SP, Jones RN, Mendes RE, et al. In vitro activity of dalbavancin against drug-resistant Staphylococcus aureus isolates from a global surveillance program. Antimicrob Agents Chemother. 2015;59:5007–5009.
   PubMed Web of Science ®Google Scholar
• Sweeney D, Shinabarger DL, Arhin FF, et al. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 2017;87:121–128.
   PubMed Web of Science ®Google Scholar
• Duncan LR, Sader HS, Smart JI, et al. Telavancin activity in vitro tested against a worldwide collection of gram-positive clinical isolates (2014). J Glob Antimicrob Resist. 2017;10:271–276.
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing. 27 edn. Wayne, PA: Clinical Laboratory Standards Institute; 2017.
   Google Scholar
• Wilson SE, Graham DR, Wang W, et al. Telavancin in the treatment of concurrent Staphylococcus aureus bacteremia: a retrospective analysis of ATLAS and ATTAIN studies. Infect Dis Ther. 2017;6:413–422.
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Barriere SL, Rubinstein E, et al. Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia. Int J Antimicrob Agents. 2013;42:367–369.
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Lentnek A, O’Riordan W, et al. A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis. 2014;14:289, Epub 2014/06/03.
   PubMed Web of Science ®Google Scholar
• Ruggero MA, Peaper DR, Topal JE. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis. Infect Dis (Lond). 2015;47:379–384.
   PubMed Web of Science ®Google Scholar
• Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40:374–380.
   PubMed Web of Science ®Google Scholar
• Werth BJ, Jain R, Hahn A, et al. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect. 2017. DOI: 10.1016/j.cmi.2017.07.028.
   PubMed Web of Science ®Google Scholar
• Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60:254–262.
   PubMed Web of Science ®Google Scholar
• Kaatz GW, Seo SM, Aeschlimann JR, et al. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1998;42:981–983.
   PubMed Web of Science ®Google Scholar
• ZYVOX® [package insert]. New York, NY: Pfizer, Inc; 2015. Available at http://www.zyvox.com/.
   Google Scholar
• Wise R, Andrews JM, Boswell FJ, et al. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother. 1998;42:721–728.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Mendes RE, Streit JM, et al. Five-year summary of in vitro activity and resistance mechanisms of linezolid against clinically important gram-positive cocci in the United States from the LEADER surveillance program (2011–2015). Antimicrob Agents Chemother. 2017;61:e00609-17.
   PubMed Web of Science ®Google Scholar
• Moise PA, Forrest A, Birmingham MC, et al. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother. 2002;50:1017–1026.
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim SH, Kim MJ, et al. Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J Infect. 2012;65:505–512.
   PubMed Web of Science ®Google Scholar
• Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38:521–528.
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Maggiore CR, Cole P, et al. Ceftaroline fosamil for the treatment of bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. Infect Dis Clin Pract (Baltim Md). 2015;23:39–43.
   PubMedGoogle Scholar
• Kelley WL, Jousselin A, Barras C, et al. Missense mutations in PBP2A affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998. Antimicrob Agents Chemother. 2015;59:1922–1930.
   PubMed Web of Science ®Google Scholar
• Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541–2546.
   PubMed Web of Science ®Google Scholar
• Cosimi RA, Beik N, Kubiak DW, et al. Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review. Open Forum Infect Dis. 2017;4:ofx084.
   PubMed Web of Science ®Google Scholar
• Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2017;61:e02015-16.
   PubMed Web of Science ®Google Scholar
• Furtek KJ, Kubiak DW, Barra M, et al. High incidence of neutropenia in patients with prolonged ceftaroline exposure. J Antimicrob Chemother. 2016;71:2010–2013.
   PubMed Web of Science ®Google Scholar
• Blumenthal KG, Kuhlen JL Jr., Weil AA, et al. Adverse drug reactions associated with ceftaroline use: a 2-center retrospective cohort. J Allergy Clin Immunol Pract. 2016;4:740–746.
   PubMed Web of Science ®Google Scholar
• Dilworth TJ, Leonard SN, Vilay AM, et al. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Clin Ther. 2014;36:1334–1344.
   PubMed Web of Science ®Google Scholar
• Hagihara M, Wiskirchen DE, Kuti JL, et al. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2012;56:202–207.
   PubMed Web of Science ®Google Scholar
• Leonard SN. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. PLoS One. 2012;7:e42103.
   PubMed Web of Science ®Google Scholar
• Holubar M, Meng L, Deresinski S. Bacteremia due to methicillin-resistant Staphylococcus aureus: new therapeutic approaches. Infect Dis Clin North Am. 2016;30:491–507.
   PubMed Web of Science ®Google Scholar
• Casapao AM, Jacobs DM, Bowers DR, et al. Early administration of adjuvant beta-lactam therapy in combination with vancomycin among patients with methicillin-resistant Staphylococcus aureus bloodstream infection: a retrospective, multicenter analysis. Pharmacotherapy. 2017;37:1347–1356.
   PubMed Web of Science ®Google Scholar
• Truong J, Veillette JJ, Forland SC. Outcomes of vancomycin plus a beta-lactam versus vancomycin only for the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2017;62:e01554-17.
   PubMed Web of Science ®Google Scholar
• Dhand A, Sakoulas G. Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Clin Ther. 2014;36:1303–1316.
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Brown J, Lamp KC, et al. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the cubicin outcomes registry and experience. Clin Ther. 2009;31:1936–1945.
   PubMed Web of Science ®Google Scholar
• Berti AD, Sakoulas G, Nizet V, et al. beta-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013;57:5005–5012.
   PubMed Web of Science ®Google Scholar
• Mehta S, Singh C, Plata KB, et al. beta-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother. 2012;56:6192–6200.
   PubMed Web of Science ®Google Scholar
• Claeys KC, Smith JR, Casapao AM, et al. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother. 2015;59:1969–1976.
   PubMed Web of Science ®Google Scholar
• Fabre V, Ferrada M, Buckel WR, et al. Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. Open Forum Infect Dis. 2014;1:ofu046.
   PubMedGoogle Scholar